Table 4. Association of LINE-1 and Alu methylation with cancer mortality.
Methylation | Person-years | All cancers | Prostate cancer | Lung cancer | Colorectal cancer | Other cancers | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|||||||
No. | HR (95% CI)a | No. | HR (95% CI)a | No. | HR (95% CI)a | No. | HR (95% CI)a | No. | HR (95% CI)a | ||
LINE-1 (%5mC) | |||||||||||
Quartileb | |||||||||||
Q4 (86.2-78.5) | 1,287 | 3 | Ref. | 0 | Ref. | 0 | Ref. | 0 | Ref. | 3 | Ref. |
Q3 (78.4-77.2) | 1,207 | 3 | 1.0 (0.2-4.8) | 1 | N/A | 1 | N/A | 0 | N/A | 1 | 0.3 (0.03-3.3) |
Q2 (77.1-75.9) | 1,298 | 11 | 3.3 (0.9-11.9) | 1 | N/A | 3 | N/A | 1 | N/A | 6 | 1.9 (0.5-7.7) |
Q1 (75.8-68.1) | 1,230 | 10 | 2.9 (0.8-10.7) | 3 | N/A | 0 | N/A | 1 | N/A | 6 | 1.6 (0.4-6.6) |
P-trend=0.031 | P-trend=0.093 | P-trend=0.598 | P-trend=0.250 | P-trend=0.232 | |||||||
Medianb | |||||||||||
High (86.2-77.2) | 2,494 | 6 | Ref. | 1 | Ref. | 1 | Ref. | 0 | Ref. | 4 | Ref. |
Low (77.1-68.1) | 2,528 | 21 | 3.2 (1.3-7.9) | 4 | 4.5 (0.5-41.5) | 3 | 4.0 (0.3-47.6) | 2 | N/A | 12 | 2.6 (0.8-8.1) |
Alu (%5mC) | |||||||||||
Quartileb | |||||||||||
Q4 (32.4-26.8) | 1,355 | 4 | Ref. | 1 | Ref. | 0 | Ref. | 0 | Ref. | 3 | Ref. |
Q3 (26.7-26.1) | 1,149 | 4 | 1.2 (0.3-4.9) | 0 | N/A | 2 | N/A | 0 | N/A | 2 | 0.8 (0.1-4.8) |
Q2 (26.0-25.6) | 1,245 | 12 | 3.4 (1.1-10.9) | 2 | 2.0 (0.2-23.3) | 2 | N/A | 1 | N/A | 7 | 2.5 (0.6-10.0) |
Q1 (25.5-23.0) | 1,323 | 8 | 2.1 (0.6-7.2) | 2 | 1.4 (0.1-16.7) | 0 | N/A | 1 | N/A | 5 | 1.6 (0.4-7.0) |
P-trend=0.103 | P-trend=0.504 | P-trend=0.671 | P-trend=0.226 | P-trend=0.285 | |||||||
Medianb | |||||||||||
High (32.4-26.1) | 2,504 | 8 | Ref. | 1 | Ref. | 2 | Ref. | 0 | Ref. | 5 | Ref. |
Low (26.0-23.0) | 2,568 | 20 | 2.5 (1.1-5.8) | 4 | 3.3 (0.4-30.5) | 2 | 1.5 (0.2-12.1) | 2 | N/A | 12 | 2.3 (0.8-6.6) |
%5mC percentage of 5-methyl cytosine, CI confidence interval, HR hazard ratio, N/A not available
Adjusted by age, BMI, race, education, smoking, pack-years, and alcohol drinking
The quartiles and the medians of LINE-1 or Alu measures were based on values among subjects free of baseline cancers